RSV F protein mutant as well as preparation method and application thereof
By designing the amino acid mutation of the RSV F protein, a stable pre-fusion conformation was formed, and the problem of insufficient safety and immunogenicity of the existing RSV vaccines was solved, and stronger immune induction efficacy and vaccine stability were achieved.
Patent Information
- Application Number
- CN202410654099.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-30
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
The existing RSV F protein vaccines have problems of insufficient safety and weak immunogenicity, making it difficult to effectively prevent serious diseases caused by respiratory syncytial virus.
By introducing amino acid mutations, RSV F protein mutants were designed, including cysteine substitution, cavity filling mutation, proline-containing artificial ligation sequence substitution and electrostatic mutation, forming a stable pre-fusion conformation and combining heterologous three The polymerization domain increases its immunogenicity and expression.
It significantly improves the immunogenicity of the RSV F protein, enhances the neutralizing antibody response and binding antibody response to RSV, improves the safety and stability of the vaccine, and is suitable for various RSV vaccine forms.
Smart Images

Figure BDA0004857341960000131 
Figure BDA0004857341960000141 
Figure BDA0004857341960000142
Abstract
Description
Technical Field
[0001] The present application belongs to the field of biomedicine technology, and in particular relates to a RSV F protein mutant, a preparation method thereof, and an application thereof in the preparation of a respiratory syncytial virus vaccine. Background Art
[0002] Human Respiratory Syncytial Virus (hRSV) is one of the main causes of severe respiratory diseases in infants and the elderly. Since the discovery of hRSV in the 1950s, domestic and foreign researchers have conducted extensive research and development on hRSV vaccines. hRSV vaccines have always faced huge challenges such as insufficient safety or weak immunogenicity, and many hRSV vaccines that have entered the clinical trial stage have been declared "failed". In 2013, after the successful analysis of the conformation of the prefusion F protein (Pre-F), the hRSV vaccine based on Pre-F showed good application prospects. Although there have been a lot of studies on the stability of the prefusion conformation of RSV F protein, its safety and effectiveness as a vaccine still face huge challenges.
[0003] Therefore, providing a RSVPre-F protein with good safety, high expression level, enhanced immunogenicity and improved stability, and a vaccine containing the same has become a technical problem that technicians in this field urgently need to solve. Summary of the invention
[0004] To solve the above technical problems, the present invention discloses a RSV F protein mutant, a preparation method thereof and an application thereof in the preparation of a respiratory syncytial virus vaccine. The F protein mutant introduces a mutation in the amino acid sequence relative to the amino acid sequence of the corresponding wild-type RSV F protein, and the mutation includes substitution, deletion or addition of amino acids.
[0005] The present invention provides a RSV F protein mutant, which comprises a soluble F protein polypeptide, wherein the F protein polypeptide comprises at least one modification selected from the following group:
[0006] (a) at least one amino acid residue is substituted by cysteine;
[0007] (b) at least one cavity-filling mutation;
[0008] (c) part or all of the fusion peptide is replaced by an artificial linker sequence containing proline; and
[0009] (d) Addition of amino acid sequences containing heterologous trimerization domains.
[0010] In some embodiments, the at least one modification comprises substitution of at least one amino acid residue in the F1 subunit and / or the F2 subunit of the F protein polypeptide with cysteine.
[0011] In some embodiments, the amino acid residue substituted with cysteine comprises at least one of positions 54, 89, 151, 159, 231, 288, and 291 of the amino acid sequence of the wild-type RSV F protein.
[0012] In some embodiments, the amino acid residue substituted with cysteine comprises at least one of T54, A89, G151, H159, L231, I288 and I291 in the amino acid sequence of the wild-type RSV F protein.
[0013] In some embodiments, the at least one cavity-filling mutation is a mutation of at least Asn at position 67 of the wild-type RSV F protein amino acid sequence.
[0014] In some embodiments, the Asn at position 67 is mutated to Phe or Trp.
[0015] In some embodiments, the portion of the fusion peptide replaced by the artificial linker sequence includes at least amino acid residues 137 to 144 of the wild-type respiratory syncytial virus F protein.
[0016] On the one hand, the present invention provides an F protein mutant, wherein at least one amino acid residue in the F1 subunit and / or F2 subunit of the wild-type respiratory syncytial virus F protein is substituted by cysteine; compared with the wild-type respiratory syncytial virus F protein amino acid sequence, Asn at position 67 is mutated to Phe or Trp; and part or all of the fusion peptide is substituted by an artificial linker sequence containing proline, wherein the amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0017] In some embodiments, the cysteine substitution comprises at least one of T54C, A89C, G151C, H159C, L231C, I288C, and I291C.
[0018] The cysteine substitution allows a non-native disulfide bond to be formed between the F1 subunit and the F2 subunit, or within the F1 subunit, of the respiratory syncytial virus F protein mutant, wherein the non-native disulfide bond includes disulfide bonds other than Cys69-Cys212 and Cys37-Cys439 formed between the F1 subunit and the F2 subunit.
[0019] In the pre-fusion conformation of RSV F protein, the β2 and β4 chains are close to each other, promoting the spatial folding of the two discontinuous epitopes of the Φ epitope; by adding non-natural disulfide bonds, the spatial position between the β2 and β4 chains can be relatively stabilized, thus stabilizing the Pre-F protein structure well.
[0020] In some embodiments, the cysteine substitution is selected from any one or two of H159C+I291C, A89C+L231C, G151C+I288C, and T54C+G151C.
[0021] In some embodiments, the cysteine is substituted as H159C+I291C, so that an intrachain disulfide bond is formed between positions 159 and 291 of the F protein mutant.
[0022] In some embodiments, the cysteine substitution is A89C+L231C, and A89C and L231C form an interchain disulfide bond between positions 89 and 231 of the F protein mutant.
[0023] In some embodiments, the cysteine substitution is T54C+G151C, and T54C and G151C form an interchain disulfide bond between positions 54 and 151 of the F protein mutant.
[0024] In some embodiments, the cysteine is substituted with G151C+I288C, so that an intrachain disulfide bond is formed between positions 151 and 288 of the F protein mutant.
[0025] In some embodiments, in order to maintain the spatial conformation and stability formed by the two discontinuous epitope peptides aa62-69 and aa196-209 before the fusion of epitope Φ, hydrophobic amino acids are replaced in the region between the β1 and β2, and / or β3 and β4 structures near the epitope, and the space-filling effect of multiple side chain hydrophobic amino acids is utilized to maintain the pre-fusion conformation of epitope Φ.
[0026] In some embodiments, the F protein mutant has at least one cavity-filling mutation compared to the wild-type respiratory syncytial virus F protein, and the mutation comprises N67F or N67W.
[0027] In some embodiments, the cavity-filling mutation is N67F.
[0028] In some embodiments, the cavity-filling mutation is N67W.
[0029] In some embodiments, part of the fusion peptide is replaced by an artificial linker sequence containing proline, and the fusion peptide is amino acid residues 137 to 157 of the wild-type respiratory syncytial virus F protein.
[0030] In some embodiments, the substituted portion of the fusion peptide is at least amino acid residues 137 to 144 of the wild-type respiratory syncytial virus F protein.
[0031] In some embodiments, the substituted portion of the fusion peptide is amino acid residues 137 to 144 of the wild-type respiratory syncytial virus F protein.
[0032] In some embodiments, the substituted portion of the fusion peptide is amino acid residues 137 to 146 of the wild-type respiratory syncytial virus F protein.
[0033] In some embodiments, the amino acid sequence of the artificial linker sequence is selected from GGPGGS, GGPGPGSE, GAPGS, GAPEPGE, GAPAPAPKPGE or GKPAPGE, and the artificial linker sequence containing proline can form a β-turn to stabilize the pre-fusion conformation of the RSV F protein.
[0034] In some embodiments, M 103 GAPGSM 145 For example, the part replaced by the artificial linker sequence "GAPGS" is the 103rd to 144th amino acid residues of the wild-type respiratory syncytial virus F protein; 137 GAPGSM 145 For example, the portion replaced by the artificial linker sequence "GAPGS" is the 137th to 144th amino acid residues of the wild-type respiratory syncytial virus F protein.
[0035] In some embodiments, the amino acid sequence of the artificial linker sequence is preferably GAPGS.
[0036] In some embodiments, the amino acid sequence of the artificial linker sequence is preferably GGPGGS.
[0037] In some embodiments, the amino acid sequence of the artificial linker sequence is preferably GKPAPGE.
[0038] In some embodiments, the amino acid sequence of the artificial linker sequence is preferably GAPEPGE.
[0039] In some embodiments, the amino acid sequence of the artificial linker sequence is preferably GGPGPGSE.
[0040] In some embodiments, the F protein mutant further has at least one electrostatic mutation selected from L138K, D486A and E487P relative to the wild-type RSV F protein.
[0041] In some embodiments, the electrostatic mutation is L138K.
[0042] In some embodiments, the electrostatic mutations are D486A and E487P.
[0043] In some embodiments, the C-terminus of the F protein mutant comprises a heterologous trimerization domain selected from foldon or GCN4.
[0044] In some embodiments, the heterologous trimerization domain contained in the C-terminus of the F protein mutant is preferably foldon.
[0045] In some embodiments, the trimerization domain can be connected to the F1 subunit or its functional fragment via a linker (such as an amino acid linker, for example, the sequence GG, GS or SAIG). The linker can also be a longer linker, for example, including a repeating sequence GG.
[0046] The F1 subunit of the F protein mutant can have the same length as the full-length F1 polypeptide of the corresponding wild-type RSV F protein; however, it can also have a deletion, such as 1, 2, 3, 5, 10, 20 amino acid residues, up to 60 amino acid residues from the C-terminus of the full-length F1 polypeptide. The full-length F1 polypeptide of the F protein mutant corresponds to amino acid positions 137-574 of the native RSV F0 precursor, and includes (from N-terminus to C-terminus) an extracellular domain (residues 137-524), a transmembrane domain (residues 525-550), and a cytoplasmic domain (residues 551-574).
[0047] In some embodiments, the F1 subunit of the F protein mutant lacks the entire cytoplasmic domain. In other embodiments, the F1 subunit lacks the cytoplasmic domain and a portion or all of the transmembrane domain. In some embodiments, the F protein mutant comprises an F1 domain, wherein the amino acid residues from positions 510, 511, 512, 513, 514, 515, 520, 525 or 530 to 574 do not exist. Typically, for the F protein mutant connected to the trimerization domain, amino acid 514 to 574 may not exist. Therefore, in some embodiments, amino acid residues 514 to 574 do not exist in the F1 subunit of the F protein mutant. In other embodiments, the F1 subunit of the F protein mutant comprises amino acid residues 137-513 of the native F0 polypeptide sequence.
[0048] The present invention further provides a RSV F protein mutant, comprising a soluble F protein polypeptide, wherein the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0049] (a) amino acid 67 is mutated from Asn to Phe or Trp;
[0050] (b) part or all of the fusion peptide is replaced by an artificial linker sequence containing proline; and
[0051] (c) one of the amino acids at positions 54, 151, 159, 291 and 288 is substituted by cysteine,
[0052] The amino acid sequence of the wild-type RSV F protein is shown in SEQ ID NO: 1.
[0053] In some preferred embodiments, the artificial linker sequence is GGPGGS or GAPGS.
[0054] In some embodiments, the portion of the fusion peptide replaced by the artificial linker sequence includes at least amino acid residues 137 to 144 of the wild-type respiratory syncytial virus F protein. For example, the portion of the fusion peptide replaced by the artificial linker sequence can be amino acid residues 137 to 144, 137 to 145, 146, 147, 148, 149, 150, 152, 153, 154, 155, 156 or 157 of the wild-type respiratory syncytial virus F protein.
[0055] In some specific embodiments, the portion of the fusion peptide replaced by the artificial linker sequence is the 137th to 144th amino acid residues of the wild-type respiratory syncytial virus F protein.
[0056] In some specific embodiments, the portion of the fusion peptide replaced by the artificial linker sequence is the 137th to 146th amino acid residues of the wild-type respiratory syncytial virus F protein.
[0057] In some preferred embodiments, the cysteine substitution is selected from T54C+G151C, G151C+I288C or H159C+I291C.
[0058] In some preferred embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0059] (a) The amino acid at position 67 was mutated from Asn to Phe;
[0060] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GAPGS;
[0061] (c) Cysteine substitution H159C+I291C,
[0062] The amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0063] In some preferred embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0064] (a) The amino acid at position 67 was mutated from Asn to Trp;
[0065] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GAPGS;
[0066] (c) Cysteine substitution H159C+I291C,
[0067] The amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0068] In some preferred embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0069] (a) The amino acid at position 67 was mutated from Asn to Phe;
[0070] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GGPGGS;
[0071] (c) cysteine substitution T54C+G151C,
[0072] The amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0073] In some preferred embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0074] (a) The amino acid at position 67 was mutated from Asn to Trp;
[0075] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GGPGGS;
[0076] (c) cysteine substitution T54C+G151C,
[0077] The amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0078] In some preferred embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0079] (a) The amino acid at position 67 was mutated from Asn to Phe;
[0080] (b) amino acid residues 137 to 146 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GAPGS;
[0081] (c) cysteine substitution T54C+G151C,
[0082] The amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0083] In some embodiments, the F protein polypeptide undergoes further electrostatic mutations at amino acids 486 and 487 relative to the wild-type RSV F protein.
[0084] In some embodiments, the electrostatic mutations are D486A and E487P.
[0085] In some specific embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0086] (a) The amino acid at position 67 was mutated from Asn to Phe;
[0087] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GAPGS;
[0088] (c) cysteine substitution H159C+I291C;
[0089] (d) electrostatic mutations D486A and E487P, the amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0090] In some specific embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0091] (a) The amino acid at position 67 was mutated from Asn to Phe;
[0092] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GAPGS;
[0093] (c) cysteine substitutions G151C+I288C;
[0094] (d) electrostatic mutations D486A and E487P, the amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0095] In some specific embodiments, the F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation:
[0096] (a) The amino acid at position 67 was mutated from Asn to Phe;
[0097] (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GGPGGS;
[0098] (c) cysteine substitutions T54C+G151C;
[0099] (d) electrostatic mutations D486A and E487P, the amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO: 1.
[0100] In some embodiments, the C-terminus of the F protein mutant comprises a heterologous trimerization domain. In some embodiments, the heterologous trimerization domain is a foldon trimerization domain or a GCN4 trimerization domain.
[0101] In some specific embodiments, the heterologous trimerization domain contained in the C-terminus of the F protein mutant is a foldon trimerization domain, and the N-terminus of the foldon trimerization domain is connected to the C-terminus of the soluble F protein polypeptide.
[0102] In some preferred embodiments, the amino acid sequence of the mutant is shown in any one of SEQ ID NO: 15, 16, 26, 43, 45, 27, 28, and 44.
[0103] Many sequences of the F protein mutants of the present invention include protease cleavage site sequences, such as thrombin cleavage site (LVPRGS); protein tags, such as 6×His-tag (HHHHHH) and StrepII tag (WSHPQFEK); or linker sequences (such as GG, GS, SAIG), which are not necessary for the function of RSV F protein, such as inducing immune response. Those skilled in the art will recognize such sequences, and understand, when appropriate, that these sequences are not included in the disclosed F protein mutants.
[0104] The foldon or foldon domain of the present invention generally refers to the residues at the C-terminus of the phage T4 fiber protein. In the present application, the foldon domain can be the 27 residues at the C-terminus of the phage T4 fiber protein or a mutant thereof. An example is a sequence having GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 7). In the present application, the foldon domain can be a truncation or an extension obtained by truncating the 27 residues at the C-terminus of the phage T4 fiber protein or increasing 1, 2, 3, 4, 5, 6 or 10 amino acids at the N-terminus or C-terminus. The mutant mentioned here generally refers to a sequence that is different from a reference sequence because it contains one or more differences (mutations). The difference can be a substitution, deletion or insertion of one or more amino acids.
[0105] The present invention also provides a kind of recombinant nucleic acid on the other hand, it comprises the polynucleotide sequence of encoding the above-mentioned F protein mutant.In certain embodiments, the recombinant nucleic acid is codon optimized to express in selected prokaryotic or eukaryotic host cells.The host cell comprising F protein mutant encoding nucleic acid is also a feature of the present invention.Advantageous host cells include prokaryotic (i.e. bacterial) host cells, such as Escherichia coli (E.coli), and many eukaryotic host cells, including fungal (e.g. yeast) cells, insect cells and mammalian cells (such as CHO, VERO, HEK293 and Expi293F cells).
[0106] The present invention also provides a method for preparing the F protein mutant, comprising the following steps:
[0107] S1, synthesizing the DNA sequence corresponding to the F protein mutant and cloning it into a plasmid vector;
[0108] S2, transfecting host cells with the recombinant plasmid vector and expressing the recombinant plasmid vector, wherein the host cells are eukaryotic cells;
[0109] S3. Purify the culture product to obtain the F protein mutant.
[0110] Another aspect of the present invention provides the use of any of the above-mentioned F protein mutants in the preparation of a vaccine for preventing RSV infection.
[0111] The present invention further provides a vaccine comprising any one of the above-mentioned F protein mutants and a pharmaceutically acceptable carrier or excipient.
[0112] In some embodiments, the F protein mutant contained in the single-dose human vaccine is derived from RSV subtype A and / or subtype B. In some embodiments, the single-dose human vaccine contains 60 to 120 μg of the F protein mutant, for example, 60, 70, 80, 90, 100, 110, 120 μg, or any value between 60 and 120 μg. In some embodiments, the single-dose human vaccine preferably contains 60 μg of the F protein mutant. In some embodiments, the single-dose human vaccine preferably contains 120 μg of the F protein mutant.
[0113] In some embodiments, the single dose of the human vaccine contains 60 μg of an F protein mutant derived from RSV A subtype and 60 μg of an F protein mutant derived from RSV B subtype.
[0114] In some embodiments, the single dose of the human vaccine contains 60 μg of an F protein mutant derived from RSV A subtype, or 60 μg of an F protein mutant derived from RSV B subtype.
[0115] In some embodiments, the single dose of the human vaccine contains 120 μg of an F protein mutant derived from RSV A subtype, or 120 μg of an F protein mutant derived from RSV B subtype.
[0116] In some embodiments, the carrier or excipient comprises a buffer. Pharmaceutically acceptable carriers and excipients are well known and can be selected by those skilled in the art. Optionally, a pharmaceutically acceptable carrier or excipient also contains at least one component that stabilizes solubility and / or stability. Examples of solubilizers / stabilizers include detergents, such as laurel sarcosine and / or tween. Other examples of solubilizers / stabilizers include arginine, sucrose, trehalose, etc. Therefore, those skilled in the art can select suitable excipients and carriers to produce formulations suitable for use by a selected route of use to a subject. Suitable excipients include, but are not limited to, glycerol, polyethylene glycol, KCl, calcium ions, magnesium ions, manganese ions, zinc ions, and other divalent cation-related salts, etc.
[0117] The vaccine provides protection against at least one infection of RSV subtype A and subtype B. The amino acid sequences of the F proteins of subtypes A and B are approximately 90% identical. An example sequence of the F0 precursor polypeptide of subtype A is provided in SEQ ID NO: 1 (A2 strain; GenBank: AAB86664.1), and an example sequence of the F0 precursor polypeptide of subtype B is provided in SEQ ID NO: 2 (18537 strain; Swiss-Prot: P13843.1). Both are sequences of 574 amino acids, wherein the signal peptide sequence has also been reported as amino acids 1-25. In both sequences, the TM domain is approximately amino acids 530 to 550, but is alternatively reported as 525-548. The cytoplasmic tail region starts at amino acids 548 or 550 and ends at amino acids 574, wherein the palmitoylated cysteine residue is located at amino acid 550.
[0118] In some embodiments, the vaccine further comprises an adjuvant.
[0119] In some embodiments, the adjuvant comprises at least one of aluminum adjuvant, squalene, tocopherol, MPL, LPA, CpG, poly(I:C) and QS-21.
[0120] Generally, an adjuvant should be selected to enhance a Th1 biased immune response in a subject or subject population to which the vaccine is administered and to be safe and effective in the subject or subject population.
[0121] Optionally, the vaccine may also contain at least one other antigen of a pathogenic organism different from RSV, for example, a virus different from RSV, such as herpes zoster virus, human papillomavirus, hepatitis B virus, coronavirus or influenza virus. Alternatively, the pathogenic organism may be a bacterium, such as diphtheria, tetanus, pertussis, Haemophilus influenzae or pneumococcus.
[0122] The present invention also provides a method for preparing the above-mentioned vaccine for preventing RSV infection, which comprises:
[0123] S1, culturing mammalian host cells to express the F protein mutant;
[0124] S2, purified expressed F protein mutants;
[0125] S3. The purified F protein mutants and adjuvants are packaged separately or fully mixed according to the proportion.
[0126] In some embodiments, the method further comprises additional steps such as gene synthesis, construction of expression vectors, and freeze-drying of purified proteins. The expressed F protein mutant can be recovered and purified from recombinant cell cultures by any one or more of many methods known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, filtration, ultrafiltration, centrifugation, anion / cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. Finally, high performance liquid chromatography HPLC can be used in the final purification step.
[0127] Compared with the prior art, the present invention has the following beneficial effects:
[0128] The present invention obtains a pre-fusion conformation of RSV F protein that can expose more neutralizing antibody epitopes by performing a single or multiple amino acid mutation combination on the wild-type RSV F protein, and even a mutant with multiple amino acid combination mutations maintains a stable pre-fusion conformation while ensuring that it can cause effective neutralizing antibody response and binding antibody response to RSV. More specifically, the present invention uses F protein mutants as immunogens in combination with adjuvants to obtain a stronger immune induction effect, greatly improving the immunogenicity of RSV antigens. The mutation method disclosed in the present invention is applicable to other virus strains of human RSV; it is applicable to various vaccine forms with RSV F protein as an antigen, such as protein vaccines, nucleic acid vaccines, virus-like particle vaccines, and vector vaccines. DETAILED DESCRIPTION
[0129] The present invention will be further described below by non-limiting examples, and it is well known to those skilled in the art that many modifications may be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention. The following examples are only intended to illustrate the present invention and should not be considered to limit the scope of the present invention, because the embodiments are necessarily diverse. The terms used in this specification are only intended to illustrate specific embodiments, and not as a limitation, and the scope of the present invention is defined in the appended claims.
[0130] Unless otherwise specified, all technical and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which this invention belongs. The preferred methods and materials of the present invention are described below, but any methods and materials similar or equivalent to those described in this specification can be used to implement or test the present invention. The following experimental methods are conventional methods or methods described in product specifications unless otherwise specified, and the experimental materials used can be easily obtained from commercial companies unless otherwise specified.
[0131] Definition of terms
[0132] In the present application, when "one embodiment" is mentioned, it means that the specific parameters, steps, etc. described in the embodiment are at least included in one embodiment of the present invention. Therefore, in the present application, if terms such as "according to one embodiment of the present invention" or "in one embodiment" are used, they are not used to specifically refer to the same embodiment, and if terms such as "in another embodiment", "according to different embodiments of the present invention", or "according to another embodiment of the present invention" are used, they are not used to specifically refer to that the mentioned features can only be included in specific different embodiments. It should be understood by those skilled in the art that the specific parameters, steps, etc. disclosed in one or more embodiments of the present specification can be combined in any suitable manner.
[0133] In the present application, the term "cavity filling mutation" refers to the amino acid replacement of the amino acid residue in the wild-type RSV F protein by the expected filling of the internal cavity of the mature RSV F protein. In a kind of application, such cavity filling mutation helps to stabilize the pre-fusion configuration of the F protein before the fusion of the recombinant RSV. The cavity in the pre-fusion configuration of the RSV F protein can be identified by methods known in the art, such as by visual inspection in the crystal structure of the RSV F of the pre-fusion configuration, or by using a computational protein design software.
[0134] In this application, the term "electrostatic mutation" refers to an amino acid mutation introduced into a wild-type RSV F protein that reduces ionic repulsion or increases ionic attraction between residues that are close to each other in a folded structure in the protein. Since hydrogen bonding is a special case of ionic attraction, electrostatic mutations can increase hydrogen bonding between such close residues.
[0135] In the present application, the term "DS-Cav1" refers to a form of RSV F protein having the amino acid sequence described in McLellan et al., Science, 342(6158), 592-598, 2013, which has stability and immunogenicity superior to wild-type (WT) RSV F protein and post-fusion F protein (post-F). The specific amino acid sequence used in the present application is shown in SEQ ID NO: 3.
[0136] In the present application, pXCS847 refers to a RSV F protein mutant designed with reference to Pfizer CN108738312A, which has major amino acid mutations T103C; I148C; S190I; D486S. The specific amino acid sequence used in the present application is shown in SEQ ID NO:4.
[0137] In the present application, PreF-1345 refers to a form of RSV F protein designed with reference to Moderna's CN115103682A, which has major amino acid mutations S155C; S290C; A149C; Y458C; S190F; V207L. The specific amino acid sequence used in the present application is shown in SEQ ID NO:5.
[0138] In the present application, the term "D25" refers to the antibody described in CN101778866B, which has an amino acid sequence of heavy chain CDR1: NYIIN, heavy chain CDR2: GIIPVLGTVHYAPKFQG, heavy chain CDR3: ETALVVSTTYLPHYFDN and light chain CDR1: QASQDIVNYLN, light chain CDR2: VASNLET, light chain CDR3: QQYDNLP. D25 is a RSV Pre-F pre-fusion conformation specific monoclonal antibody.
[0139] In the present application, the term "101F" refers to the antibody described in US20060159695A1, which has the amino acid sequence of heavy chain CDR1: TSGMGVS, heavy chain CDR2: HIYWDDDKRYNPSLKS, heavy chain CDR3: LYGFTYGFAY and light chain CDR1: RASQSVDYNGISYMH, light chain CDR2: AASNPES, light chain CDR3: QQIIEDPWT.
[0140] In the present application, the term "Mota" or "motavizumab" refers to the antibody described in WO2007002543A2, which has the amino acid sequence of heavy chain CDR1: TSGMSVG, heavy chain CDR2: DIWWDDKKDYNPSLKS, heavy chain CDR3: SMITNWYFDV and light chain CDR1: SASSRVGYMH, light chain CDR2: DTSKLAS, light chain CDR3: FQGSGYPFT.
[0141] In this application, the term "include" generally means to include, encompass, contain or encompass. In some cases, it also means "for", "consisting of...".
[0142] Example 1. Single mutant design and gene synthesis
[0143] The F protein mutants of the present invention are designed and prepared based on the wild-type (abbreviated as WT) RSV F protein amino acid sequence described in SEQ ID NO: 1. This example illustrates the design of various F protein mutants, which include a foldon domain and introduced amino acid mutations.
[0144] The template amino acid sequence before the introduction of amino acid mutations is:
[0145] MELLILKANAITTILTAVTFCFASG QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSA IASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIATVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITND QKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKY DCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL SAIG GYIPEAPRDGQAYVRKDGEWVLLSTFL GG LVPRGSHHHHHHSAWSHPQFEK (SEQ ID NO:8).
[0146] The amino acid sequence designed according to the table below was codon-optimized according to the host Expi293F cells to determine the nucleic acid sequence for full gene synthesis.
[0147] Table 1 Design of cysteine-substituted mutants
[0148]
[0149]
[0150] Table 2 Mutant design of cavity filling mutations
[0151]
[0152]
[0153] Table 3 Design of mutants containing proline artificial linker sequence substitution
[0154]
[0155]
[0156] Table 4 Design of mutants for electrostatic mutation
[0157] Mutant ID mutation DM-17 L503E,I506K DM-18 F488W DM-19 E487Y DM-20 F137I,G143I DM-23 F140I,S146V DM-27 L138K DM-30 F488P,D489G DM-31 F488P,D489P DM-32 D486P,E487P,F488G DM-33 D486P,E487G,F488P DM-34 D486A,E487P DM-37 E487P
[0158] Table 5 Control group design
[0159] Control group SEQ ID NO: WT 1 DS-Cav1 3 pXCS847 4 PreF-1345 5 Post-F 6
[0160] Example 2. Construction, expression and preliminary screening of recombinant plasmids
[0161] The synthesized target gene was inserted into the eukaryotic plasmid PTT5 vector and used to transfect Expi293F cells for expression. Expi293F cells in the logarithmic growth phase were passaged one day before transfection and seeded in a 96-well deep-well plate at a certain cell density so that the cell density reached 2.5×10 6 / ml. Dilute 0.8μg antigen expression plasmid in 40μl Opti-MEMI, and dilute 2.4μl transfection reagent in 40μl Opti-MEM. Mix the diluted DNA and transfection reagent separately and incubate at room temperature for 20min. Add the DNA-liposome complex to the cells and culture at 37°C, 5% CO2, 3mm orbital oscillator, 1200rpm. Collect the cell supernatant after 3 days of expression, and use the double antibody sandwich ELISA method, using 101F (site IV specific antibody that binds to both pre-fusion and post-fusion F) as the coating antibody and D25 (specifically recognizes pre-fusion F protein) as the coating antibody. The expression of Siteφ and SiteⅡ epitopes of each mutant was detected by using OD values.
[0162] The specific steps of the double antibody sandwich ELISA method are:
[0163] 1) Solution preparation
[0164] Coating solution: sodium bicarbonate 1.59g / L, sodium bicarbonate 2.94mg / L;
[0165] 20mM PB solution: disodium hydrogen phosphate; sodium dihydrogen phosphate;
[0166] Blocking solution: 0.02M PB, 1.5% BSA + 5% sucrose, 0.1% Proclin300;
[0167] Diluent: 0.02M PB, 1.5% BSA, 0.1% Proclin 300, aminopyrine.
[0168] 2) Antibody coating: dilute the 101F antibody to 4 μg / ml with coating solution, add 100 μl / well into the wells of the ELISA plate, and incubate at 2-8°C for 16 hours.
[0169] 3) Blocking: Wash twice with a plate washer at 300 μl / well, pat dry, add blocking solution at 150 μl / well, incubate at 37°C for 2 hours.
[0170] 4) Sample addition: Add the sample to be tested and enzyme-labeled antibody (2000-fold dilution), 100 μl / well, incubate at 37°C for 30 minutes, and wash the plate 5 times using a plate washer.
[0171] 5) Color development: Add 100 μl / well of color development solution (A+B) and react for 15 minutes at room temperature in the dark.
[0172] 6) Reading: Open the microplate reader in advance, allow color development to complete, add 50 μl / well of stop solution to the reaction wells of the microplate, and place it in the microplate reader (dual wavelength, 450nm / 630nm) for reading.
[0173] The designs with high expression levels obtained in the initial screening were used for the next step of screening or evaluation. The results are shown in the following table.
[0174] Table 6 Preliminary screening of cysteine-substituted mutants by high-throughput transfection expression in 96-well plates
[0175]
[0176]
[0177]
[0178] Mutants CM-2, CM-5, CM-6, CM-8, CM-14, CM-15, CM-18, CM-19, CM-23, CM-26, CM-27, CM-28, CM-32, CM-33, CM-34 and CM-35 can stably maintain the neutralizing antibody epitopes Siteφ and SiteⅡ and can be used for the next step of screening and evaluation.
[0179] Table 7 Preliminary screening of cavity filling mutants by high-throughput transfection expression in 96-well plates
[0180]
[0181]
[0182] Mutants VM-3, VM-4, VM-5, VM-6, VM-8, VM-10, VM-11, VM-12, VM-14, and VM-15 can stably maintain the neutralizing antibody epitopes Siteφ and SiteⅡ and can be used for the next step of screening and evaluation.
[0183] Table 8 Preliminary screening of mutants containing proline artificial linker sequence substitution by high-throughput transfection expression in 96-well plates
[0184]
[0185]
[0186] Table 9 Preliminary screening of electrostatic mutants by high-throughput transfection expression in 96-well plates
[0187]
[0188] Note: “ / ” indicates no reactivity detected or not determined
[0189] The above mutants can all stably maintain the neutralizing antibody epitope Siteφ and can be used for the next step of screening and evaluation.
[0190] Example 3. Evaluation of expression and stability of single mutants
[0191] Expi293F cells in the logarithmic growth phase were passaged one day before transfection at a rate of 1.2×10 6 The cells were inoculated into a 96-well deep-well plate at a density of 2.5 × 10 / ml. 6 / ml. Use Opti-MEMI to dilute the expression plasmid and transfection reagent respectively, let it stand at room temperature for 5 minutes, gently drop the transfection reagent PEI into the diluted DNA and mix it, and incubate it at room temperature for 20 minutes. Add the DNA-PEI complex to the cells and place it at 37°C, 5% CO2, 3mm orbital shaker, and culture it at 1200rpm. After three days of single mutant expression, the expressed cell supernatant was collected by centrifugation at 10000rpm, and the expression supernatant was taken separately and stored at 4°C for 7 days and 14 days respectively. Then, the double antibody sandwich ELISA method was used, with 101F as the coating antibody, D25 and motavizumab (hereinafter referred to as Mota) as the labeled antibody detection pair, to detect the expression amount of each mutant expressed by the recombinant plasmid, and the conformational stability of Siteφ and SiteⅡ epitopes after being placed at 4°C for different times, among which the expression amount was expressed by the epitope-specific neutralizing antibody detection activity concentration, and the conformational stability was expressed by the activity concentration ratio of day14 / day0. The results are shown in the following table.
[0192] Table 10 Expression level and conformational stability screening of cysteine-substituted mutants
[0193]
[0194]
[0195] Note: “ / ” indicates no reactivity detected or not determined
[0196] Table 11 Conformational stability of cysteine substituted mutants
[0197]
[0198] Note: “ / ” indicates no reactivity detected or not determined
[0199] After comprehensive consideration of expression and thermal stability, the cysteine-substituted mutants CM-2, CM-18, CM-19, CM-28, CM-35, CM-33 and CM-14 performed better. Compared with the wild type, the D25 activity concentration did not decrease significantly or did not decrease after storage at 4°C for 14 days, and the pre-fusion conformation retention rate was significantly higher than that of the wild-type F protein. And it has comparable or higher stability than DS-Cav1.
[0200] Table 12 Expression level and conformational stability screening of cavity filling mutation mutants
[0201]
[0202] Note: “ / ” indicates no reactivity detected or not determined
[0203] Table 13 Conformational stability of the mutants with cavity filling mutations
[0204]
[0205]
[0206] After comprehensive consideration of expression and thermal stability, mutants VM-4 and VM-5 performed better. Compared with the wild type, the D25 activity concentration did not decrease significantly or did not decrease after storage at 4°C for 14 days, and the pre-fusion conformation retention rate was significantly higher than that of the wild-type F protein. And it has comparable stability to DS-Cav1.
[0207] Table 14 Expression and conformational stability screening of mutants containing proline artificial linker sequence substitution
[0208]
[0209]
[0210] Note: “ / ” indicates no reactivity detected or not determined
[0211] Table 15 Conformational stability of mutants containing proline artificial linker sequence substitution
[0212]
[0213]
[0214] After comprehensive consideration of expression and thermal stability, mutants LM-6, LM-7, LM-8, LM-9 and LM-12 performed better. Compared with the wild type, the D25 activity concentration did not decrease significantly or did not decrease after storage at 4°C for 14 days, and the pre-fusion conformation retention rate was significantly higher than that of the wild-type F protein. And it has comparable or higher stability than DS-Cav1.
[0215] Table 16 Expression level and conformational stability screening of electrostatic mutation mutants
[0216]
[0217]
[0218] Note: “ / ” indicates no reactivity detected or not determined
[0219] Table 17 Conformational stability of mutants with electrostatic mutations
[0220]
[0221] After comprehensive consideration of expression and thermal stability, the mutant DM-27 performed better. Compared with the wild type, the D25 detection activity concentration did not decrease significantly after storage at 4°C for 14 days, and the pre-fusion conformation retention rate was significantly higher than that of the wild-type F protein. And it has comparable stability to DS-Cav1.
[0222] Example 4. Design of exemplary combined mutants, expression level and stability evaluation
[0223] Based on the above research, the preferred single mutation information was combined in a permutation and combination manner to design a combined mutant. The signal peptide of the template amino acid sequence was replaced with the CD33 signal peptide (SEQ ID NO: 9), and the linker between the foldon domain and the F1 subunit was replaced with GGSGGSG. The single mutants with better expression and thermal stability screened out above were used as the design basis. The amino acid sequence was designed according to the table below and codon optimization was performed according to the host Expi293F cells to determine the nucleic acid sequence for full gene synthesis. The recombinant plasmid was constructed and expressed according to the method of Example 2.
[0224] Table 18 Combination mutant design
[0225]
[0226]
[0227]
[0228] After three days of expression of the combined mutants, the expressed cell supernatant was collected by centrifugation at 10,000 rpm, and the expression supernatant was taken separately and incubated at 50°C and 60°C for 1 hour respectively. Then, the double antibody sandwich ELISA method was used, with 101F as the coating antibody and D25 as the labeled antibody detection pair, to detect the expression level of each mutant expressed by the recombinant plasmid, and the conformational stability of the Siteφ epitope after incubation at 4°C, 50°C for 1h and 60°C for 1h. Among them, the expression level was expressed as the epitope-specific neutralizing antibody detection activity concentration, and the conformational stability was expressed as the activity concentration ratio of 50°C / 4°C and 60°C / 4°C. The results are shown in the following table.
[0229] Table 19 Expression level and conformational stability of combined mutants
[0230]
[0231]
[0232]
[0233] Compared with the control group, mutants RC175, RC201, RC202, RC250, RC251, RC254, RC268, RC269, RC270, RC271, RC273, RC315, RC319 and RC320 basically showed higher expression levels, and had conformational stability comparable to or better than that of the control group at 50°C or even 60°C. As vaccine immunogen components, they can ensure temporary storage within 1 hour under extreme temperature conditions of 50-60°C.
[0234] Example 5. Protein preparation
[0235] 5.1 Large-scale protein expression
[0236] Recombinant proteins were expressed by transient transfection in Expi293F cells using PEI MAX. Expi293F cells in logarithmic growth phase were passaged one day before transfection and cultured at 2.5 × 10 6 / ml cell density was inoculated in a 500ml / 1000ml shake flask. On the day of transfection, the cell density was diluted to 2.5×10 6 / ml, dilute the expression plasmid DNA and transfection reagent PEI MAX with Opti-MEM respectively, let stand at room temperature for 5 minutes, gently drop the diluted transfection reagent PEI MAX into the diluted expression plasmid DNA and mix well, and incubate at room temperature for 10 minutes. Add the DNA-PEI complex to the cells and culture them in a carbon dioxide shaker at 37°C, 8% CO2, and 120rpm. Collect the culture supernatant on the 4th day after transfection, and remove cell debris by centrifugation twice at 4000rpm and 10000rpm. The culture supernatant was sterile filtered, and the protein was purified by HiS Trap HP and StrepII two-step affinity chromatography.
[0237] 5.2 Protein purification
[0238] Turn on the SCG chromatography system and connect the instrument, adjust the system parameters so that the pressure does not exceed 0.3Mpa and the bubble alarm is highly sensitive, centrifuge the cell supernatant to be purified at 10000rpm for 8min, and then filter for later use. Use a two-step chromatography method to purify the expressed immunogenic protein.
[0239] (1) HiS Trap HP (5ml) chromatography: First, 50ml Buffer A (20mM PB, 500mM NaCl, pH7.4) was used to equilibrate the chromatography column (HiS Trap HP 5ml) at a flow rate of 5ml / min for 10 minutes. After equilibration, the supernatant was filtered before loading at a flow rate of 2ml / min. After loading, 50ml Buffer A (20mM PB, 500mM NaCl, pH7.4) was used to rinse the chromatography column at a flow rate of 5ml / min for 10 minutes until the UV light approached the baseline position, and then buffer B (20mMPB, 500mM NaCl, 500mM Imidazole, pH 7.4) was used to elute the immunogenic protein at a flow rate of 5ml / min.
[0240] (2) StrepII (1 ml) chromatography: 30 ml Buffer C (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0) was used to equilibrate the column (StrepII purification column) at a flow rate of 1 ml / min until the UV reached the baseline; HiSTrap HP (5 ml) chromatography eluent was loaded at a flow rate of 1 ml / min. After loading, the column was equilibrated with Buffer C at a flow rate of 1 ml / min until the UV reached the baseline; finally, Buffer D (50 mM biotin in Binding Buffer) was used to elute the immunogenic protein at a flow rate of 1 ml / min. After rinsing with pure water, the column was washed with NaOH (50 mM) to regenerate.
[0241] Quantification: Mix the eluted protein and quantify it by UV280nm. Take out a small amount of protein for electrophoresis detection and aliquot the rest and freeze at -80℃.
[0242] 5.3 Protein purity detection
[0243] (1) Sample processing
[0244] The sample was centrifuged at 10000 rpm / min for 5 minutes. 40 μl of the supernatant was taken and mixed thoroughly with 10 μl of loading buffer.
[0245] (2) Gel plate assembly: Take out the precast gel, tear off the bottom tape, carefully remove the sample slot template, and fix it in the electrophoresis tank. Pour the electrophoresis buffer into the front and rear tanks. The liquid in the inner tank must cover the gel loading hole. The liquid level in the outer tank should not exceed the liquid level in the inner tank.
[0246] (3) Sample loading: 5 μg / well of sample mixture, 20 μl of negative control mixture per well, and 5 μl of marker.
[0247] (4) Electrophoresis: Cover the top cover, connect the electrophoresis instrument, turn on the electrophoresis instrument, adjust the voltage to 80 V, and start electrophoresis. When the blue bromophenol blue band reaches the junction of the concentrated gel and the separation gel, adjust the voltage to 100 V and continue electrophoresis. Stop electrophoresis when the blue band reaches the bottom.
[0248] (5) Gel treatment
[0249] Pre-wash: Soak the film in ultrapure water, shake it at a constant speed for 5 minutes, and repeat 3 times.
[0250] Staining: Take out the film from the ultrapure water, soak it in the staining solution, and shake it at a constant speed for 1 hour.
[0251] Destaining: Take out the film from the staining solution, soak it in ultrapure water, and shake it at a constant speed for 1 hour until the gel background is transparent.
[0252] (6) Result processing: Use a gel imaging system to take pictures of the gel and save the pictures.
[0253] Example 6. Identification and Characterization of Exemplary Immunogens
[0254] 6.1 Evaluation of immunogen conformational stability
[0255] The stability of the purified protein immunogen conformation was identified using the Pre-F pre-fusion conformation-specific monoclonal antibody D25. The stability of the candidate immunogen conformation under different temperatures, osmotic pressures, and repeated freeze-thaw conditions was investigated, and the affinity of the candidate immunogen to the D25 monoclonal antibody was tested.
[0256] Table 20 Investigation conditions
[0257]
[0258] 6.2 Identification of immunogens and study of aggregate forms
[0259] The immunogen was identified by SDS-PAGE detection method. The molecular weight of the candidate immunogen was determined by HPLC method, and the polymer form of the target molecule was determined by comparing the molecular weight with the theoretical molecular weight of the immunogen design.
[0260] Table 21 F protein mutant protein characterization
[0261]
[0262]
[0263] Note: “ / ” indicates no reactivity detected or not determined
[0264] Each F protein mutant contains the natural furin cleavage site and pep27 of the wild-type RSV F protein, but the mutation disclosed in the present invention is sufficient to stabilize it in the pre-fusion conformation, and the ratio of the D25 neutralizing antibody detection activity concentration before treatment under conditions of placement at 50°C for 1 hour, high / low osmotic pressure, and repeated freezing and thawing is close to 1, especially the mutants RC175, RC201, RC202, RC250, RC251, RC254, RC315, RC319 and RC320 after being placed at 60°C for 1 hour, the stability is comparable to the DS-Cav1 and pXCS847 levels of the control group, among which RC175, RC201, RC202, RC250, RC251, RC254, RC315, RC319 and RC320 all exist in a stable trimer form.
[0265] Example 7. Immunological Evaluation of Exemplary Candidate Antigens
[0266] Female BALB / C mice aged 6-8 weeks were selected for immunization and randomly divided into groups of 6 mice each. The mice were double-point immunized with vaccines by intramuscular injection on days 0 and 21, with 50 μL in each left and right leg, including exemplary F protein mutant candidate antigens RC175, RC201, RC202, RC250, RC251, RC254, RC315, RC319 and RC320; DS-Cav1 control antigen group; and PBS negative control group. The antigen dose was 12 μg / mouse, and the emulsion adjuvant (hereinafter referred to as adjuvant) dose was 1 / 20 HD per mouse (1 HD emulsion adjuvant is 0.5 ml, containing 50 μg MPL, 50 μg QS-21, 1 mg DOPC, 0.25 mg cholesterol, 4.835 mg sodium chloride, 0.15 mg anhydrous disodium hydrogen phosphate, 0.54 mg potassium dihydrogen phosphate and water for injection). Sera were collected on the 20th and 35th days, respectively, and stored at -20°C for subsequent neutralizing antibody and binding antibody testing.
[0267] 7.1 Binding antibody detection:
[0268] (1) Dilute the serum sample to be tested with sample diluent;
[0269] (2) Negative control serum was diluted 1:200 with sample diluent;
[0270] (3) Sample loading: Add the serially diluted serum samples to be tested and negative control serum to the pre-F ELISA plate at 100 μl / well, with the serum samples to be tested added to 1 well and the control solution added to 2 wells; add the sample diluent to the IgG-UNLB ELISA plate at 100 μl / well;
[0271] (4) Incubation: Incubate the ELISA plate at 37°C for 30 min and wash the plate five times with washing buffer in an automatic plate washer;
[0272] (5) Add enzyme: Add 100 μl / well of enzyme-labeled secondary antibody (HRP Goat Anti-Mouse IgG (H+L), ABclonal) to the ELISA plate, incubate at 37°C for 30 min, and wash the plate five times with washing buffer in an automatic plate washer;
[0273] (6) Color development: Mix equal volumes of color development solution A and color development solution B (Feijing Biotechnology), add 100 μl / well to the ELISA plate, and incubate at room temperature in the dark for 15 min;
[0274] (7) Termination: Add 50 μl / well of stop solution to terminate the reaction;
[0275] (8) Plate reading: The absorbance was measured at a wavelength of 450 nm (reference wavelength was 620 nm) using an ELISA reader. The results are shown in the following table.
[0276] Table 22 (3-week serum) Pre-F specific IgG content
[0277]
[0278]
[0279] Note: “ / ” indicates that the data cannot be measured due to the animal’s own physical illness during the breeding process.
[0280] Table 23 (5-week serum) Pre-F specific IgG content
[0281]
[0282]
[0283] Note: “ / ” indicates that the data cannot be measured due to the animal’s own physical illness during the breeding process.
[0284] Table 24 (3-week serum) Pre-F specific IgG content
[0285]
[0286]
[0287] Table 25 (5-week serum) Pre-F specific IgG content
[0288]
[0289] The results showed that when mice were immunized with only control protein or candidate antigen, the IgG GMC (geometric mean concentration) detected in the mouse serum was low, whether 3 weeks or 5 weeks after immunization. The booster immunization could increase the measured binding antibody level to varying degrees, and the addition of emulsion adjuvant could provide a better protective effect when RSV virus invaded. When mice were immunized with candidate antigens and adjuvants, the IgG GMC (geometric mean concentration) detected in the mouse serum was greatly increased, especially at 5 weeks after immunization, a very high level of binding antibodies was produced. In addition to RC175, the combined mutants RC254, RC319, RC250, RC320, RC202, RC251 and RC315 induced binding antibody levels far exceeding the DS-Cav1 control group, and the combined mutant RC201 also obtained Pre-F IgG GMC comparable to the DS-Cav1 control group, with good immunogenicity.
[0290] 7.2 Neutralizing Antibody Detection:
[0291] We commissioned Zhongke Guobang to use RSV A2 strain to conduct neutralizing antibody testing through the fluorescent spot reduction neutralization test (FRNT method). The specific steps are:
[0292] (1) Sample preparation: serum stored at -20°C was thawed at room temperature, heat inactivated at 56°C for 30 min, taken out after 30 min and cooled to room temperature, and then the six serum samples in each group were fully mixed to obtain mixed serum samples for each group.
[0293] (2) Sample loading and dilution: 40-fold initial dilution, followed by 4-fold dilution, for 6 dilutions. Take a 96-well plate, use the second column as the cell control (CC), and the third column as the virus control (VC). Add the 20-fold diluted sample to wells B4-B11, use a multichannel pipette to gently mix the liquid in wells B4-B11, and then perform a 4-fold dilution until wells G4-G11. Take another negative reference sample for loading and dilution.
[0294] (3) Virus dilution: Dilute the virus to 800-1200 FFU / well on ice and add to each well except the cell control.
[0295] (4) Place the above 96-well plate in a 37°C, 5% CO2 incubator and incubate for 1 hour.
[0296] (5) HEp-2 cells were digested and counted and adjusted to 2.0×10 using complete culture medium. 5 pcs / mL, 100 μL / well was added into a 96-well plate.
[0297] (6) The cells were cultured in a 37° C., 5% CO 2 incubator. After 24-28 hours, GFP fluorescent spots were counted using a cell imaging multifunctional microplate detection system and the results were recorded.
[0298] (7) 50% neutralizing antibody inhibition rate (ND 50 ) calculation: the fluorescence spot value read by the instrument is input into the data analysis template, and the 50% neutralizing antibody inhibition rate (ND 50 ), and the results are shown in the following table.
[0299] Table 26 Neutralizing antibody titer
[0300]
[0301]
[0302] Table 27 Neutralizing antibody titer
[0303]
[0304] After booster immunization, the titer of induced neutralizing antibodies increased significantly. The titer of neutralizing antibodies in the serum of mice 5 weeks after immunization with RC201 and RC202 combined with adjuvants was approximately 48 times and 37 times that of the group without adjuvant, respectively. The use of adjuvants further improved the immunogenicity. The titer of neutralizing antibodies produced 5 weeks after immunization with RC201 and RC202 combined with adjuvants was approximately 23 times and 27 times that of the group without adjuvant, respectively. The titer of neutralizing antibodies produced in the serum of mice 5 weeks after immunization with RC315, RC319, RC320, RC254, RC250 and RC251 combined with adjuvants was approximately 45 times, 37 times, 49 times, 50 times, 28 times and 40 times that of the group without adjuvant, respectively. The neutralizing antibody test results further demonstrated the excellent immunogenicity of the combined mutants RC254, RC319, RC250, RC320, RC202, RC201, RC251 and RC315. Except that the neutralizing antibody titer induced by RC201 had no statistical difference with that of the DS-Cav1 control group, the remaining combined mutants induced more neutralizing antibodies than DS-Cav1. Moreover, compared with the ratio of the neutralizing antibody titer produced 5 weeks after immunization with DS-Cav1 combined with adjuvant to that of the group without adjuvant (W5 serum--adjuvanted / no adjuvant=5), and the ratio of the neutralizing antibody titer in the mouse serum 5 weeks after combined adjuvant immunization to that at 3 weeks (combined adjuvant-W5 serum / W3 serum=25), the candidate antigens of the present invention have greatly improved the neutralizing antibody level. In summary, the immune evaluation results prove that the combined mutants RC201, RC202, RC250, RC315, RC320, RC251, RC254 and RC319 have excellent immunogenicity, and can all be used as potential candidate vaccines that are superior to DS-Cav1. It can be seen from the above experiments that the F protein mutant provided by the present invention is well expressed, has high protein activity, and exhibits excellent thermal stability, storage stability, high and low osmotic stability, and freeze-thaw stability. In addition, the F protein mutant and vaccine composition provided by the present invention can induce the production of high-titer binding antibodies and neutralizing antibodies against RSV virus, which also suggests that the vaccine will provide better protective effects when the virus invades, which is of great significance to the research and development of RSV candidate vaccines.
[0305] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A RSV F protein mutant comprising a soluble F protein polypeptide, characterized in that: The F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation: (a) amino acid 67 is mutated from Asn to Phe or Trp; (b) part or all of the fusion peptide is replaced by an artificial linker sequence containing proline; and (c) one of the amino acids at positions 54, 151, 159, 291 and 288 is substituted by cysteine, The amino acid sequence of the wild-type RSV F protein is shown in SEQ ID NO:
1.
2. The F protein mutant according to claim 1, characterized in that The artificial connection sequence is GGPGGS or GAPGS.
3. The F protein mutant according to claim 2, characterized in that The portion of the fusion peptide replaced by the artificial connection sequence at least includes the 137th to 144th amino acid residues of the wild-type respiratory syncytial virus F protein.
4. The F protein mutant according to claim 3, characterized in that The part of the fusion peptide replaced by the artificial connection sequence is the 137th to 144th amino acid residues or the 137th to 146th amino acid residues of the wild-type respiratory syncytial virus F protein.
5. The F protein mutant according to claim 3 or 4, characterized in that The cysteine substitutions are T54C+G151C, G151C+I288C or H159C+I291C.
6. The F protein mutant according to claim 5, characterized in that The F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation: (a) The amino acid at position 67 was mutated from Asn to Phe; (b) amino acid residues 137 to 144 or 137 to 146 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GGPGGS or GAPGS; (c) cysteine substitutions T54C+G151C, G151C+I288C or H159C+I291C, wherein the amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO:
1.
7. The F protein mutant according to claim 5, characterized in that The F protein polypeptide undergoes the following mutations relative to the wild-type RSV F protein to stabilize the pre-fusion conformation: (a) The amino acid at position 67 was mutated from Asn to Trp; (b) amino acid residues 137 to 144 relative to wild-type respiratory syncytial virus F protein are replaced by the sequence GGPGGS or GAPGS; (c) cysteine substitutions T54C+G151C or H159C+I291C, The amino acid sequence of the wild-type RSV F protein is as shown in SEQ ID NO:
1.
8. The F protein mutant according to any one of claims 1 to 7, characterized in that The F protein polypeptide undergoes further electrostatic mutations at amino acids 486 and 487 relative to the wild-type RSV F protein.
9. The F protein mutant according to claim 8, characterized in that The electrostatic mutations are D486A and E487P.
10. The F protein mutant according to any one of claims 1 to 7, 8 or 9, characterized in that The C-terminus of the mutant contains a heterologous trimerization domain.
11. The F protein mutant according to claim 10, characterized in that The heterologous trimerization domain is a foldon trimerization domain.
12. The F protein mutant according to claim 11, characterized in that The amino acid sequence of the mutant is shown in any one of SEQ ID NOs: 15, 16, 26, 43, 45, 27, 28, and 44.
13. Use of the F protein mutant according to any one of claims 1-7, 8, 9, 10, 11-12 in preparing a vaccine for preventing RSV infection.
14. A vaccine, characterized in that Comprising the F protein mutant according to any one of claims 1-7, 8, 9, 10, 11-12 and a pharmaceutically acceptable carrier or excipient.
15. The vaccine according to claim 14, characterized in that Further comprising an adjuvant.
Citation Information
Cited By
Respiratory syncytial virus F protein mutant and application thereof
CN120329397A
